Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, […]
Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scientific and financial conferences throughout November. The Company’s most advanced Amanitin-based ADC product candidate, HDP-101, is currently in a Phase I/IIa trial for […]
HDP-101 clinical trial in Europe and US continues with adjusted protocol and dose optimization on track; sixth patient cohort dosed at 90 µg/kg and patients are still on treatment Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty New clinical data with HDP-101 presented at the International Myeloma Society (IMS) Annual meeting; […]
Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today […]
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024. Read more…
